SecBot SecBot
COURT-RULING ·Filed Mar 2, 2026

CVS

CVS HEALTH Corp
NEUTRAL
Impact 3/10
Horizonmonths Processed5mo ago CourtCourt Ruling · courtlistener.com
Court ruling (district)
Actionable Insight • Neutral

CVS's claims against Epic are dismissed without prejudice (leave to amend is standard in this MDL). Monitor whether CVS files an amended complaint re-pleading specific facts about Epic's role in the Ursodiol conspiracy. The broader MDL continues against other manufacturers, so CVS's overall antitrust recovery prospects are not eliminated.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$80.49
T+0 close · Mar 3, 2026 · via day close
Latest settled
+15.51%
T+60 · $92.97
Vs SPY
+4.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 3 $80.49entry
  2. T+1 · 9mo ago +0.10%α −0.61% · $80.57
  3. T+5 · 8mo ago −5.18%α −4.72% · $76.32
  4. T+20 · 8mo ago −10.77%α −6.36% · $71.82
  5. T+60 · 6mo ago +15.51%α +4.59% · $92.97
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

In the Generic Pharmaceuticals MDL, Judge Rufe granted in part and denied in part Epic Pharma's motions to dismiss antitrust claims. CVS's complaint against Epic was dismissed for failure to state a claim, as it lacked specific allegations linking Epic to any conspiracy regarding Ursodiol. This is a procedural win for Epic and removes CVS from this particular litigation track, but the ruling is interlocutory and does not resolve the broader MDL.

Court Ruling Details

Ruling Date
Feb 27, 2026
Court
U.S. District Court for the Eastern District of Pennsylvania
Court Level
District
Judge
Cynthia M. Rufe
Case Type
antitrust
Ruling Type
motion to dismiss
Outcome
LOSS: ruling against this company
Precedent Risk
LOW

Key Facts

  • CVS Pharmacy, Inc. v. Actavis Elizabeth, LLC, et al. (2:20-cv-06310) was one of three complaints dismissed against Epic Pharma for failure to state a claim.
  • The court found CVS's complaint lacked any specific act by Epic regarding Ursodiol, no meeting, phone call, or price hike was alleged.
  • Epic's motions to dismiss were denied as to eight other complaints (including those by Kroger, Humana, Rite Aid, Walgreens, UnitedHealth, and others) which sufficiently alleged a conspiracy.
  • The ruling is a motion-to-dismiss decision under Rule 12(b)(6); it does not adjudicate the merits of the broader antitrust conspiracy allegations.
  • CVS remains a plaintiff in the MDL against other defendants; only claims against Epic were dismissed.

Financial Impact

No damages awarded or quantified in this ruling. The dismissed complaint sought unspecified treble damages under antitrust law.

legal_exposure

Risk Factors

  • CVS may need to re-plead with greater specificity to rejoin the case against Epic.
  • If CVS does not amend, it loses any potential recovery from Epic in this MDL.
  • The ruling is interlocutory and not appealable as of right; no immediate financial impact.

Market Snapshot

Exchange
NYSE
Sector
Retail-Drug Stores and Proprietary Stores
Analyst Consensus
82% bullish (33 analysts)

Investment Themes

Consumer & Retail

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-1as9hv5f-CVS

Track record

25 reports on CVS

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +32.33% at T+60 after the Apr 8, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 13, 20264d ago Court Ruling Neutral 3/10 No price data
  2. Nov 6, 202610d ago Insider Buy Bullish 4/10 Entry $85.25 Now $88.59 +3.92% settles Dec 8
  3. Nov 4, 202612d ago 8-K Neutral 6/10 Entry $79.96 Now $88.59 +10.79% settles Dec 3
  4. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $79.96 Now $88.59 +10.79% settles Dec 3
  5. Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $92.53 Now $88.59 −4.26% settles Nov 23
  6. Oct 15, 20264w ago Press Release Neutral 2/10 Entry $92.58 to $89.79 Now $88.59 −4.31% ▼ −3.01% −1.11% vs SPY
  7. Sep 30, 20266w ago Press Release Neutral 2/10 Entry $85.20 to $90.33 Now $88.59 +3.98% ▲ +6.02% +5.32% vs SPY
  8. Aug 5, 202614w ago 8-K Bullish 8/10 Entry $99.12 to $97.23 Now $88.59 −10.62% ▼ −1.91% −1.31% vs SPY
  9. Jul 10, 202618w ago Press Release Neutral 2/10 Entry $104.15 to $95.46 Now $88.59 −14.94% ▼ −8.35% −10.77% vs SPY
  10. Jun 29, 202620w ago Court Ruling Bullish 5/10 Entry $103.58 to $107.74 Now $88.59 −14.47% ▲ +4.02% +4.30% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (9h 51m)

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · courtlistener.com Report published Jun 6, 2026